ARALEZ PHARMACEUTICALS INC. (NASDAQ:ARLZ) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 – Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
(b)In connection with Aralez Pharmaceuticals Inc.’s (the “Company’s”) winding down of its operations in connection with its bankruptcy proceedings, the employment by Company of the following individuals was or will be ceased, effective as of the dates noted below:
· Adrian Adams, Chief Executive Officer (January31, 2019)
· Andrew Koven, President and Chief Business Officer (January31, 2019)
· Jennifer Armstrong, Executive Vice President, Human Resources and Administration (January31, 2019)
· Michael Kaseta, Chief Financial Officer (January18, 2019)
Mr.Adams will continue as a member of the Board of Directors of the Company.
(c)
Effective as of January18, 2019, Sanjay Subramanian, 43, the Company’s current Treasurer, will assume the role of Chief Financial Officer. Prior to joining the company, Mr. Subramanian was the Director of Treasury at Bausch Health Companies. Mr. Subramanian started his finance career at General Motors Co. where he held various positions before leaving as the Treasurer of GM Korea.
Effective as of January31, 2019, Christopher Freeland, 40, the Company’s current General Counsel, will also assume the role of Chief Operating Officer. Prior to being appointed as the Company’s General Counsel, Mr. Freeland was the Company’s Associate General Counsel. Prior to joining the Company, Mr. Freeland was an Associate General Counsel at American International Group. Mr. Freeland started his legal career as a corporate associate at Willkie Farr & Gallagher LLP.
About ARALEZ PHARMACEUTICALS INC. (NASDAQ:ARLZ)
Aralez Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G. Its development products include YOSPRALA and Bilastine. Fibricor (fenofibric acid) is indicated as a complementary therapy along with diet for the treatment of hypertriglyceridemia, and as a complementary therapy along with diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (Total-C), triglycerides (TG) and apolipoprotein B (Apo B). Fibricor is also used to increase high-density lipoprotein (HDL) cholesterol (HDL-C) in patients with hypercholesterolemia or mixed dyslipidemia. Cambia (diclofenac potassium for oral solution) is a non-steroidal anti-inflammatory drug (NSAID).